Comparative Pharmacology
Head-to-head clinical analysis: EFAVIRENZ LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFAVIRENZ LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE versus EMTRICITABINE.
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EFAVIRENZ: Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing allosteric inhibition and blocking RNA-dependent DNA polymerase activity. LAMIVUDINE: Nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to its active triphosphate metabolite, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, causing chain termination. TENOFOVIR DISOPROXIL FUMARATE: Prodrug of tenofovir, an NRTI that, after hydrolysis and phosphorylation, inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine triphosphate and causing DNA chain termination.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (efavirenz 600 mg, lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg) orally once daily on an empty stomach, preferably at bedtime.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Efavirenz: 40-55 h (single dose), 50-76 h (multiple doses). Lamivudine: 5-7 h (adults). Tenofovir: 17 h (single dose), 12-17 h (multiple doses) in cells up to 48-60 h. Clinical context: Efavirenz's long half-life allows once-daily dosing; tenofovir's long intracellular half-life supports once-daily dosing.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Efavirenz: 14-34% renal (mostly metabolites), 16-61% fecal (parent drug and metabolites). Lamivudine: ~70% renal (unchanged via active tubular secretion). Tenofovir disoproxil fumarate: 70-80% renal (unchanged as tenofovir via glomerular filtration and active secretion).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI